ClinicalTrials.gg
CompletedNCT04544956B-FineUpdated Jul 15, 2025Results posted

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

A Phase 2 interventional study of GSK3228836 and Nucleos(t)ide therapy in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
16th of 16
12 · median 103
Started
2020
with 1 other
Phase 2
7 of 16
1 open now
Registered
3rd of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 16th largest by enrollment, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 3rd registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

Hepatitis B virus (HBV) infection, especially chronic, is a significant worldwide medical problem. This is an exploratory study of the therapeutic mechanism of GSK3228836 in participants with chronic hepatitis B (CHB) on stable nucleos(t)ide therapy (which is the first line therapy for CHB). This study is a Phase IIa, multi-center open label exploratory study of the therapeutic mechanism of GSK3228836 in participants with hepatitis B virus e-antigen (HBeAg)-negative CHB on stable nucleos(t)ide therapy using repeat fine needle aspirations of the liver for intrahepatic immunophenotyping. It will investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine needle aspirates of the liver will be performed to enable analysis of liver-resident immune cells to investigate any immunomodulatory properties of GSK3228836 and to study the biology of underlying treatment-associated liver flares. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately 20 participants will be enrolled in the study.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Hepatitis B virus
  • GSK3228836
  • Fine needle aspiration
  • Intrahepatic immunophenotyping
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants should be at least 18 years of age at the time of signing the .
  • Participants who have documented chronic infection >=6 months prior to screening and currently receiving stable nucleos(t)ide analogue therapy, defined as no changes to their nucleos(t)ide regimen from at least 6 months prior to screening and with no planned changes to the stable regimen over the duration of the study.
  • Plasma or serum HBsAg concentration >100 IU/mL
  • Plasma or serum HBV DNA concentration must be adequately suppressed, defined as plasma or serum HBV DNA \<90 IU/mL.
  • HBeAg-negative
  • less than or equal to (\<=)2 times
  • No gender restriction.
  • A male participant is eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study treatment i. Refrain from donating sperm ii. and be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or Must agree to use /barrier as detailed below

    1) Agree to use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak) when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant.

  • A female participant is eligible to participate:

    i. If she is not pregnant or breastfeeding. ii. and at least one of the following conditions applies:

    1. Is not a WOCBP
    2. or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1 percent [%] per year), preferably with low user dependency during the intervention period and for at least 90 days after the last dose of study treatment iii. A WOCBP must have both

    <!-- -->

    1. A confirmed menstrual period prior to the first dose of study intervention (additional evaluation [e.g. amenorrhea in athletes, birth control] should also be considered)
    2. and a negative highly sensitive pregnancy test (urine or serum) within 24 hours before the first dose of study treatment
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • abnormalities, aside from chronic infection in medical history (e.g., moderate-severe liver disease other than chronic HBV, acute coronary syndrome within 6 months of screening, major surgery within 3 months of screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis or coagulopathy) or physical examination.
  • Co-infection with:

    1. Current or past history of virus (HCV)
    2. (HIV)
    3. Hepatitis D virus (HDV).
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by

    1. Both (AST)- Index (APRI) >2 and FibroSure/FibroTest result >0.7

      1) If only one parameter (APRI or FibroSure/FibroTest) result is positive, a discussion with the Medical Monitor is required before inclusion in study is permitted.

    2. Regardless of APRI or Fibrosure/FibroTest score participants will be excluded from the study if their past history includes one of the following criteria:

      1. Liver showing Metavir 4 or equivalent
      2. Liver stiffness >12 kilopascals (kPa)
  • Diagnosed or suspected hepatocellular carcinoma as evidenced by the following

    1. Alpha-fetoprotein concentration >=200 nanograms (ng)/mL
    2. If the screening alpha fetoprotein concentration is >=50 ng/mL and \<200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before enrolment.
  • History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
  • History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause) or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  • History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
  • Anti-neutrophil cytoplasmic antibody (ANCA) at screening by itself won't be an exclusion criterion - but if results are borderline positive or positive:

    1. Myeloperoxidase (MPO)-ANCA (perinuclear [p] ANCA) and Proteinase 3 (PR3)-ANCA (Cytoplasmic [c] ANCA) analysis will be conducted
    2. A discussion with the Medical Monitor will be required to review participant's complete medical history to ensure no past history or current manifestations of a vasculitic/inflammatory/auto-immune condition before inclusion in study is permitted.
  • Low compliment (C)3 at screening or Baseline by itself won't be an exclusion criterion-but if it is present

    a. A discussion with the Medical Monitor is required to review participant's complete medical history to ensure no past history or current manifestations of vasculitic/inflammatory/auto-immune conditions.

  • History of alcohol or drug abuse/dependence

    1. Current alcohol use as judged by investigator to potentially interfere with participant compliance.
    2. History of or current drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance.

      1. Refers to illicit drugs and substances with abuse potential. Medications that are used by the participant as directed, whether over-the-counter or through prescription, are acceptable and would not meet the exclusion criteria.
  • Currently taking, or took within 3 months of screening, any drugs (e.g., prednisone), other than a short course of therapy (\<=2 weeks) or topical/inhaled use.
  • Participants for whom immunosuppressive treatment is not advised, including therapeutic doses of steroids, will be excluded.
  • Currently taking, or took within 12 months of screening, any interferon-containing therapy.
  • Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors or anti-platelet agents like clopidogrel).
  • The participant has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 5 half-lives (if known) or twice the duration (if known) of the biological effect of the study treatment (whichever is longer) or 90 days (if half-life or duration is unknown).
  • Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 12 months prior to the first dosing day.
  • Fridericia's correction formula (QTcF) >=450 milliseconds (msec) (if single [ECG] at screening shows QTcF >=450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
  • Laboratory results as follows

    1. Serum albumin \<3.5 grams per deciliter (g/dL)
    2. (GFR) \<60 mL/minute/1.73 per meter square as calculated by the Chronic kidney disease- Epidemiologic Collaboration (CKD-EPI) formula.
    3. (INR) >1.25
    4. Platelet count \<140 times 10\^9/liter (L)
    5. Total >1.25 times

      1. For participants with benign unconjugated hyperbilirubinemia with total bilirubin >1.25 times ULN, discussion for inclusion to the study is required with the Medical Monitor
    6. Urine albumin to creatinine ratio (ACR) >=0.03 mg/mg (or >=30 mg/g). In the event of an ACR above this threshold, eligibility may be confirmed by a second measurement 1) In cases where participants have low urine albumin and low urine creatinine levels resulting in a urine ACR calculation >=0.03 mg/mg (or >=30 mg/g), the investigator should confirm that the participant does not have a history of diabetes, hypertension or other risk factors that may affect renal function and discuss with the Medical Monitor, or designee.
  • History of/sensitivity to GSK3228836 or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    GSK3228836 300 mg

    Participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).

    Drug: GSK3228836 · Drug: Nucleos(t)ide therapy

Interventions

  • GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.

  • DrugNucleos(t)ide therapy

    Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ)

    Percentage of participants achieving serum HBsAg level \<LLOQ were reported. Percentage values are rounded-off.

    Time frame: Up to Week 12

Secondary outcomes

  1. Percentage of Participants With Sustained HBsAg Response (HBsAg <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment

    Sustained HBsAg response is defined as HBsAg \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.

    Time frame: Up to 24 weeks off treatment (Study Weeks 12 to 36)

  2. Percentage of Participants Achieving Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment

    Sustained virologic response is defined as HBsAg \<LLOQ and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.

    Time frame: Up to 24 weeks off treatment (Study Weeks 12 to 36)

  3. Percentage of Participants Achieving HBsAg <LLOQ at Indicated Time Points

    Percentage of participants achieving HBsAg \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment (OT) Day 162

  4. Percentage of Participants Achieving HBV DNA <LLOQ at Indicated Time Points

    Percentage of participants achieving HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  5. Percentage of Participants Achieving HBsAg <LLOQ and HBV DNA <LLOQ at Indicated Time Points

    Percentage of participants achieving HBsAg \<LLOQ and HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  6. Percentage of Participants With Categorical Change From Baseline in HBsAg Values at Indicated Time Points

    Participants who achieved a decline in HBsAg values from Baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from Baseline values. Percentage values are rounded-off.

    Time frame: Baseline (Week -1), Treatment Week 12 and off treatment Week 24

  7. Number of Participants With Alanine Aminotransferase (ALT) Greater Than (>)3 Times Upper Limit of Normal (ULN) at Indicated Time Points

    Blood samples were collected at indicated time points to assess ALT levels. The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with Baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

    Time frame: Baseline (Week -1), treatment Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162

  8. Number of Participants With HBe Antibody (Anti-HBeAg) Levels

    Blood samples were collected to assess HBe antibody levels and results reported are for Baseline HBeAg positive participants.

    Time frame: Baseline (Week -1), treatment Days 29, 36, and 57; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162

  9. Actual Values of HBsAg at Indicated Time Points

    Blood samples were collected from participants at indicated time points to assess HBsAg levels.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  10. Mean Change From Baseline in HBsAg at Indicated Time Points

    Blood samples were collected from participants at indicated time points to assess HBsAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  11. Actual Values of HBV DNA at Indicated Time Points

    Blood samples were collected from participants at indicated time points to assess HBV DNA levels.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  12. Mean Change From Baseline in HBV DNA at Indicated Time Points

    Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162

  13. Actual Values of HB Surface Antibody (Anti-HBsAg) Levels at Indicated Time Points

    Blood samples were collected from participants at indicated time points to assess anti-HBsAg levels.

    Time frame: Baseline (Week -1) and off treatment Days 1 and 162

  14. Area Under the Concentration-time Curve (AUC) for ALT at Indicated Time Points

    Blood samples were collected from participants to assess AUC for ALT. On-treatment blood samples were collected from Weeks 1 to 12 and follow-up blood samples were collected from Weeks 12 to 36. AUC was calculated and presented for on-treatment (12 Weeks), follow-up (24 weeks), and On-treatment + follow-up (Weeks 1 to 36).

    Time frame: Study Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 28, 32 and 36

  15. Time to Maximum ALT

    Time to maximum ALT (maximum peak in ALT) during 36 week (treatment + follow-up) is defined as time from Baseline to the time of first peak in ALT.

    Time frame: Up to Study Week 36

07

Results

Posted Dec 19, 2024

Participant flow

This was an open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in participants with Chronic Hepatitis B via intrahepatic immunophenotyping.

Participant flow — Overall Study
MilestoneGSK3228836 300 mg
Started12
Completed11
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ)

Percentage of participants achieving serum HBsAg level \<LLOQ were reported. Percentage values are rounded-off.

Time frame:
Up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ)
Percentage of participantsGSK3228836 300 mg
Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ)25
SecondaryPercentage of Participants With Sustained HBsAg Response (HBsAg <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment

Sustained HBsAg response is defined as HBsAg \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.

Time frame:
Up to 24 weeks off treatment (Study Weeks 12 to 36)
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained HBsAg Response (HBsAg <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment
Percentage of participantsGSK3228836 300 mg
Sustained HBsAg Response for 24 Weeks after Planned End of GSK3228836 Treatment8
Sustained HBsAg Response for 24 Weeks after Actual End of GSK3228836 Treatment8
SecondaryPercentage of Participants Achieving Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment

Sustained virologic response is defined as HBsAg \<LLOQ and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.

Time frame:
Up to 24 weeks off treatment (Study Weeks 12 to 36)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment
Percentage of participantsGSK3228836 300 mg
Sustained Virologic Response for 24 Weeks after Planned End of GSK3228836 Treatment8
Sustained Virologic Response for 24 Weeks after Actual End of GSK3228836 Treatment8
SecondaryPercentage of Participants Achieving HBsAg <LLOQ at Indicated Time Points

Percentage of participants achieving HBsAg \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment (OT) Day 162
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HBsAg <LLOQ at Indicated Time Points
Percentage of participantsGSK3228836 300 mg
Baseline (Week -1)0
Treatment Day 7830
Off Treatment Day 16218
SecondaryPercentage of Participants Achieving HBV DNA <LLOQ at Indicated Time Points

Percentage of participants achieving HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HBV DNA <LLOQ at Indicated Time Points
Percentage of participantsGSK3228836 300 mg
Baseline (Week -1)92
Treatment Day 7878
Off Treatment Day 162100
SecondaryPercentage of Participants Achieving HBsAg <LLOQ and HBV DNA <LLOQ at Indicated Time Points

Percentage of participants achieving HBsAg \<LLOQ and HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HBsAg <LLOQ and HBV DNA <LLOQ at Indicated Time Points
Percentage of participantsGSK3228836 300 mg
Baseline (Week -1)0
Treatment Day 7820
Off Treatment Day 16218
SecondaryPercentage of Participants With Categorical Change From Baseline in HBsAg Values at Indicated Time Points

Participants who achieved a decline in HBsAg values from Baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from Baseline values. Percentage values are rounded-off.

Time frame:
Baseline (Week -1), Treatment Week 12 and off treatment Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Categorical Change From Baseline in HBsAg Values at Indicated Time Points
Percentage of participantsGSK3228836 300 mg
Treatment Week 12, HBsAg < LLOQ30
Treatment Week 12, HBsAg decline <0.5 log10 IU/mL10
Treatment Week 12, HBsAg decline >=0.5 log10 IU/mL90
Treatment Week 12, HBsAg decline >=1 log10 IU/mL80
Treatment Week 12, HBsAg decline >=1.5 log10 IU/mL80
Treatment Week 12, HBsAg decline >=3 log10 IU/mL50
Off Treatment Week 24, HBsAg < LLOQ18
Off Treatment Week 24, HBsAg decline <0.5 log10 IU/mL73
Off Treatment Week 24, HBsAg decline >=0.5 log10 IU/mL27
Off Treatment Week 24, HBsAg decline >=1 log10 IU/mL27
Off Treatment Week 24, HBsAg decline >=1.5 log10 IU/mL27
Off Treatment Week 24, HBsAg decline >=3 log10 IU/mL18
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Greater Than (>)3 Times Upper Limit of Normal (ULN) at Indicated Time Points

Blood samples were collected at indicated time points to assess ALT levels. The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with Baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

Time frame:
Baseline (Week -1), treatment Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162
Reported as:
Count of participants · Participants
Number of Participants With Alanine Aminotransferase (ALT) Greater Than (>)3 Times Upper Limit of Normal (ULN) at Indicated Time Points
ParticipantsGSK3228836 300 mg
Baseline (Week -1)0
Treatment Day 80
Treatment Day 150
Treatment Day 220
Treatment Day 290
Treatment Day 361
Treatment Day 431
Treatment Day 501
Treatment Day 571
Treatment Day 641
Treatment Day 711
Treatment Day 780
Off Treatment Day 10
Off Treatment Day 80
Off Treatment Day 220
Off Treatment Day 500
Off Treatment Day 780
Off Treatment Day 1061
Off Treatment Day 1340
Off Treatment Day 1620
SecondaryNumber of Participants With HBe Antibody (Anti-HBeAg) Levels

Blood samples were collected to assess HBe antibody levels and results reported are for Baseline HBeAg positive participants.

Time frame:
Baseline (Week -1), treatment Days 29, 36, and 57; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162
Reported as:
Count of participants · Participants
Number of Participants With HBe Antibody (Anti-HBeAg) Levels
ParticipantsGSK3228836 300 mg
Baseline (Week -1)11
Treatment Day 2911
Treatment Day 360
Treatment Day 579
Off Treatment Day 19
Off Treatment Day 810
Off Treatment Day 2210
Off Treatment Day 5010
Off Treatment Day 7810
Off Treatment Day 10610
Off Treatment Day 1348
Off Treatment Day 16210
SecondaryActual Values of HBsAg at Indicated Time Points

Blood samples were collected from participants at indicated time points to assess HBsAg levels.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Mean · Log10 IU/mL
Actual Values of HBsAg at Indicated Time Points
Log10 IU/mLGSK3228836 300 mg
Baseline (Week -1)3.29 ± 0.590
Treatment Day 780.33 ± 1.432
Off Treatment Day 1622.08 ± 1.933
SecondaryMean Change From Baseline in HBsAg at Indicated Time Points

Blood samples were collected from participants at indicated time points to assess HBsAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Mean · Log10 IU/mL
Mean Change From Baseline in HBsAg at Indicated Time Points
Log10 IU/mLGSK3228836 300 mg
Treatment Day 78-2.923 ± 1.5803
Off Treatment Day 162-1.183 ± 1.8343
SecondaryActual Values of HBV DNA at Indicated Time Points

Blood samples were collected from participants at indicated time points to assess HBV DNA levels.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Mean · Log10 IU/mL
Actual Values of HBV DNA at Indicated Time Points
Log10 IU/mLGSK3228836 300 mg
Baseline (Week -1)0.43 ± 0.849
Treatment Day 780.31 ± 0.611
Off Treatment Day 1620.24 ± 0.525
SecondaryMean Change From Baseline in HBV DNA at Indicated Time Points

Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Week -1), treatment Day 78 and off treatment Day 162
Reported as:
Mean · Log10 IU/mL
Mean Change From Baseline in HBV DNA at Indicated Time Points
Log10 IU/mLGSK3228836 300 mg
Treatment Day 78-0.271 ± 1.1145
Off Treatment Day 162-0.237 ± 0.7871
SecondaryActual Values of HB Surface Antibody (Anti-HBsAg) Levels at Indicated Time Points

Blood samples were collected from participants at indicated time points to assess anti-HBsAg levels.

Time frame:
Baseline (Week -1) and off treatment Days 1 and 162
Reported as:
Mean · Log10 IU/mL
Actual Values of HB Surface Antibody (Anti-HBsAg) Levels at Indicated Time Points
Log10 IU/mLGSK3228836 300 mg
Baseline (Week -1)0.60 ± 0.000
Off Treatment Day 10.71 ± 0.238
Off Treatment Day 1620.70 ± 0.260
SecondaryArea Under the Concentration-time Curve (AUC) for ALT at Indicated Time Points

Blood samples were collected from participants to assess AUC for ALT. On-treatment blood samples were collected from Weeks 1 to 12 and follow-up blood samples were collected from Weeks 12 to 36. AUC was calculated and presented for on-treatment (12 Weeks), follow-up (24 weeks), and On-treatment + follow-up (Weeks 1 to 36).

Time frame:
Study Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 28, 32 and 36
Reported as:
Mean · Weeks*International Units Per Liter
Area Under the Concentration-time Curve (AUC) for ALT at Indicated Time Points
Weeks*International Units Per LiterGSK3228836 300 mg
On-Treatment (12 Weeks)494.75 ± 562.593
Follow-up (24 weeks)650.58 ± 462.762
On-Treatment + Follow-Up (Weeks 1 to 36)1173.72 ± 836.768
SecondaryTime to Maximum ALT

Time to maximum ALT (maximum peak in ALT) during 36 week (treatment + follow-up) is defined as time from Baseline to the time of first peak in ALT.

Time frame:
Up to Study Week 36
Reported as:
Median · Weeks
Time to Maximum ALT
WeeksGSK3228836 300 mg
Time to Maximum ALTNA (27.1 to NA)

Adverse events

Collected over Up to Study Week 36. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK3228836 300 mg0/12 (0%)0/12 (0%)11/12 (91.7%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventGSK3228836 300 mg
Injection site erythemaGeneral disorders7/12
Injection site pruritusGeneral disorders4/12
Procedural painInjury, poisoning and procedural complications3/12
FatigueGeneral disorders2/12
Injection site bruisingGeneral disorders2/12
Injection site painGeneral disorders2/12
PyrexiaGeneral disorders2/12
DiarrhoeaGastrointestinal disorders2/12
DizzinessNervous system disorders2/12
HeadacheNervous system disorders2/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK3228836 300 mg
Mean48.8 ± 8.48
Sex/Gender, Customized
Sex/Gender, Customized(Participants)GSK3228836 300 mg
De-identified12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK3228836 300 mg
De-identified12
08

Study locations

4 sites
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2023, 37 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's 37 months is above that.

Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 10, 2020
StartActual
Oct 6, 2020
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Results first posted
Dec 19, 2024
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04544956
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Oct 6, 2020
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Results posted
Dec 19, 2024
Last update
Jul 15, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion